Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.

BJU international·2026
Same author

Knowledge of Dietary Supplements and Attitudes Towards Complementary Medicine Among University Students: A Cross-Sectional Study.

Foods (Basel, Switzerland)·2026
Same author

Enhancing Professional Periodontal Therapy with a Novel PMA-Zeolite Application: A Clinical Study on Periodontal Outcomes and Microbiological Changes.

Journal of functional biomaterials·2025
Same author

Synthesis, Antiproliferative Activity, and ADME Profiling of Novel Racemic and Optically Pure Aryl-Substituted Purines and Purine Bioisosteres.

Biomolecules·2025
Same author

Rectus Abdominis Muscle Endometriosis: A Unique Case Report with a Literature Review.

Current issues in molecular biology·2025
Same author

Interaction of HERVs with PAMPs in Dysregulation of Immune Response Cascade Upon SARS-CoV-2 Infections.

International journal of molecular sciences·2025

Related Experiment Video

Updated: May 14, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular

Marijana Turčić1, Kristian Krpina2,3, Dragan Trivanović4,5

  • 1Teaching Institute of Public Health of Primorsko-Goranska County, Krešimirova 52a, 51000 Rijeka, Croatia.

Cancers
|May 13, 2026
PubMed
Summary

This review explores novel therapeutic targets and strategies for renal cell carcinoma (RCC), including gene fusions, hypoxia-inducible factor-2α (HIF-2α) inhibitors, and immunotherapies. It also examines orthomolecular approaches for managing oxidative stress and tumor metabolism in advanced RCC.

Keywords:
cell-based immunotherapygenomic fusion biologymolecular targetingorthomolecular therapeutic approachesrenal cell carcinoma

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: May 14, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Renal cell carcinoma (RCC) is a complex cancer with genetic, metabolic, and immune dysregulation.
  • Distinct oncogenic mechanisms drive RCC progression, offering therapeutic intervention targets.

Purpose of the Study:

  • To provide a comprehensive overview of RCC therapeutic targets and management strategies.
  • To re-evaluate RCC management through novel molecular and immunological lenses.
  • To present orthomolecular and natural product-based therapies as potential adjunctive treatments.

Main Methods:

  • Review of molecular studies on RCC oncogenic mechanisms.
  • Analysis of therapeutic concepts targeting genomic fusions, hypoxia-driven signaling, and immune dysregulation.
  • Evaluation of novel immunotherapies and orthomolecular strategies.

Main Results:

  • Highlights TFE3 fusion proteins in translocation RCC and HIF-2α inhibitors in clear-cell RCC.
  • Discusses emerging immunotherapies like gene therapy and CAR T-cell therapy.
  • Reviews orthomolecular approaches for oxidative stress, metabolism, and immune effects.

Conclusions:

  • Integrative and precision-guided approaches are crucial for enhancing efficacy and reducing toxicity in advanced or treatment-resistant RCC.
  • Novel therapies, including immunotherapies and orthomolecular strategies, show promise for personalized RCC management.
  • Further research is needed to optimize these multidimensional frameworks for improved patient outcomes.